Fidelity Canada Investors LLC于2026年9月23日在联交所场内以每股均价41.7798港元买入金斯瑞生物科技股份279.53万股，涉资约1.17亿港元，属场内主动交易，即在二级市场直接买卖股份。
Fidelity Canada Investors LLC此次增持前持有金斯瑞生物科技好仓1.14亿股，占比4.98%；增持后持股量为1.16亿股，好仓比例升至5.1%。
Fidelity Canada Investors LLC于2026年9月23日在联交所场内以每股均价41.7798港元买入金斯瑞生物科技股份279.53万股，涉资约1.17亿港元，属场内主动交易，即在二级市场直接买卖股份。
Fidelity Canada Investors LLC此次增持前持有金斯瑞生物科技好仓1.14亿股，占比4.98%；增持后持股量为1.16亿股，好仓比例升至5.1%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.